TNTakafumi Nakano

Takafumi Nakano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takafumi Nakano has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Kenichi Mishima

    Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

    9 shared publications
  • Koichi Matsuo

    Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

    9 shared publications
  • Yoshihiko Nakamura

    Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0133, Japan

    8 shared publications
  • Hidetoshi Kamimura

    Department of Pharmacy, Fukuoka University Hospital, Fukuoka, Japan

    5 shared publications
  • Hiroyasu Ishikura

    Department of Emergency and Critical Care Medicine, Fukuoka University Hospital, Fukuoka, Japan

    5 shared publications
  • Kazunori Sano

    Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan

    5 shared publications

Latest Publications

  • Open Access

    Mitochondria-Associated mRNAs Restore ATP During Oxidative Stress via Cytosolic Translation

    by Dong-Bin Back, Gen Hamanaka, Ji-Hyun Park, Shin Ishikane, Masayoshi Tanaka, Takafumi Nakano, Yoshihiko Nakamura, Kazuhide Hayakawa

    Mitochondrial transplantation has been proposed as a strategy to restore cellular bioenergetics after oxidative injury, but the mechanisms governing ATP recovery remain unclear. Using placental mitochondria, we examined ATP restoration following H2O2-induced oxidative stress. Unmodified mitochondria modestly increased ATP under baseline conditions but failed to restore ATP after injury. In contrast, lipid-coated mitochondria (MitoCoat) and lipid-encapsulated mitochondria-associated mRNAs (MitoCoat–mRNA) significantly increased ATP levels in injured cells. Transcriptomic analyses revealed that ATP recovery occurred without the normalization of canonical glycolytic or oxidative phosphorylation (OXPHOS) gene programs. Instead, unmodified mitochondria induced broad transcriptional responses associated with immune activation and cellular stress, whereas MitoCoat elicited a more restricted transcriptional profile. Notably, mitochondria-associated mRNAs alone restored ATP without detectable changes in host transcriptional programs. The removal of mitochondrial surface-associated ribosomes or the inhibition of cytosolic but not mitochondrial translation attenuated ATP recovery. The restoration of key metabolic enzymes through cytosolic translation, including PFKP, pyruvate dehydrogenase, and ATP synthase subunit ATP5A suggests that mitochondria-associated mRNAs promote recovery by re-establishing coupling between glycolysis and mitochondrial OXPHOS. Together, these findings identify encapsulated mitochondria-associated mRNAs as a potential strategy to restore cellular bioenergetics under oxidative stress.


  • Open Access

    Temporal changes in blood haptoglobin levels after ischemic stroke in mice and humans

    by Takafumi Nakano, Ayuko Masaki, Mayuka Morimoto, Keiichi Irie, Saki Egashira, Akiko Manabe, Hiroto Iyota, Maiko Nakashio, Masanobu Uchiyama, Kazunori Sano, et al.

  • Open Access

    Clinical outcomes after switching from sulfamethoxazole-trimethoprim to atovaquone due to intolerance in patients with non-HIV Pneumocystis pneumonia: a single-center retrospective study

    by Yukino Shirakawa, Takafumi Nakano, Keisuke Sato, Yuka Takahashi, Mika Higashi, Yukiomi Eguchi, Takuya Yamashina, Tadahiro Ikeuchi, Susumu Kaneshige, Masanobu Uchiyama, et al.

    Background: Atovaquone (Atov), a second-line drug, is used to treat patients with Pneumocystis pneumonia (PCP) who cannot tolerate sulfamethoxazole/trimethoprim (SMX/TMP). However, the efficacy and safety of Atov are based on clinical trials conducted in patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome, with limited data available on HIV-uninfected individuals with PCP (non-HIV PCP). In this study, we retrospectively evaluated the clinical outcomes of switching from SMX/TMP to Atov in patients with non-HIV PCP. Methods: The study included patients with non-HIV PCP who were admitted to Fukuoka University Hospital between 2016 and 2023 and initially received SMX/TMP therapy. The primary endpoint was 30-day survival rate from the date of PCP diagnosis. Secondary endpoints included factors associated with mortality and the cumulative incidence of switching from SMX/TMP to Atov. Results: Of the 56 patients receiving SMX/TMP therapy for PCP, 17 were switched to Atov due to SMX/TMP-related side effects. The Kaplan–Meier estimated 30-day survival was 76.9% in the “remained on” SMX/TMP group and 82.4% in the “switched to” Atov group (log-rank test, P = 0.58). Univariable logistic regression analysis of 30-day mortality showed that switching to Atov was not associated with higher mortality compared with continued SMX/TMP therapy (odds ratio 0.71, 95% confidence interval 0.17 to 3.05). The Kaplan–Meier estimated cumulative incidence of switching from SMX/TMP to Atov during the PCP treatment period was 33.8%. Conclusion: Our data suggest that switching from SMX/TMP to Atov may not be associated with worse survival. Long-term administration of SMX/TMP is often challenging due to its side effects, and in this study, more than 30% of patients were unable to tolerate its therapeutic dose. Our findings support the role of Atov as a viable second-line treatment for PCP in immunocompromised patients, such as those with non-HIV PCP.


  • Open Access

    Temporal Dynamics of Haptoglobin in Acute Ischemic Stroke and HMGB1-Mediated Neuroinflammation

    by Takafumi Nakano, Mayuka Morimoto-Arimatsu, Kenichi Mishima

    Haptoglobin (Hp) is an acute-phase protein that binds free hemoglobin and limits hemoglobin-mediated oxidative injury. In addition to this established function, Hp modulates inflammatory responses and interacts with high-mobility group box 1 (HMGB1), a major damage-associated molecular pattern, suggesting a multifunctional role. Hp is primarily produced by the liver, although local expression in brain-resident cells has also been reported, potentially contributing to tissue-specific protection. This review summarizes the biological properties of Hp, including hemoglobin clearance, immune modulation, and HMGB1 scavenging, and discusses experimental and clinical evidence linking Hp to ischemic stroke. In acute ischemic stroke, secondary brain injury is mainly driven by sterile inflammation and oxidative stress. Hemoglobin-mediated toxicity appears context-dependent, particularly in cases with blood–brain barrier disruption or hemorrhagic transformation, whereas HMGB1-mediated inflammatory signaling is more consistently implicated. However, the role of endogenous Hp in regulating these processes remains incompletely understood, particularly regarding its temporal dynamics after stroke. Accumulated evidence suggests that Hp undergoes dynamic temporal changes after stroke and may contribute to the regulation of post-ischemic inflammatory and oxidative pathways. A better understanding of its multifunctional roles and temporal regulation may provide new insights into ischemic stroke mechanisms and future therapeutic strategies.

  • Therapeutic mitochondria treatment amplifies macrophage-mediated phagocytosis and recycling exocytosis

    by Masayoshi Tanaka, Shin Ishikane, Dong Bin Back, Ester Licastro, Fang Zhang, Ji Hyun Park, Elga Esposito, Giuseppe Pignataro, Takafumi Nakano, Yoshihiko Nakamura, et al.

    Therapeutic administration of mitochondria has been increasingly explored. However, how these administered mitochondria impact immune response remains to be fully addressed. In this proof-of-concept study, we show that extracellularly added mitochondria to cultured peritoneal macrophages increase phagocytosis and recycling exocytosis that amplifies neuroplasticity mediated by recycled mitochondria transfer. Macrophage activation markers such as Nos2 , Arg1 , and Cd163 were unchanged at 3 h post-treatment with mitochondria, but whole mitochondria or delivery of mRNAs extracted from whole mitochondria appeared to increase SQSTM1 protein and activate Nrf2-mediated phagocytosis in macrophages, whereas mitochondria treatment did not change the ability of phagocytosis in cultured microglia or astrocytes. Notably, the once engulfed mitochondria in macrophages appear to be released via Rab27a-mediated recycling pathway that were favorably incorporated in mechanically damaged neurons compared with healthy neurons, resulting in accelerating neurite extension in damaged neurons in a direct co-culture model. Altogether, these findings uncover unappreciated mechanisms that mitochondria-treated macrophages upregulate phagocytosis and recycling exocytosis, implicating that engineering mitochondria delivery to macrophages is a new therapeutic intervention to promote neurorecovery in CNS disorders.


  • Open Access

    Effect of Long-Term Tocolysis with Magnesium Sulfate on Maternal Renal Function in Patients with Threatened Preterm Labor

    by Tomoko Shinojima, Takafumi Nakano, Masahiro Okurano, Kaoru Kihara, Keisuke Sato, Marie Yoshioka, Masaya Adachi, Mika Higashi, Takuya Yamashina, Masanobu Uchiyama, et al.

    In Western countries, magnesium sulfate (MgSO4) for threatened preterm labor is recommended as short-term tocolysis (<48 h) considering potential maternal adverse effects. In Japan, long-term tocolysis exceeding 48 h remains common; however, its maternal renal and fetal effects remain unclear. We evaluated the impact of long-term MgSO4 tocolysis on maternal renal function. This retrospective observational study included pregnant women hospitalized for threatened preterm labor who received MgSO4 therapy at Fukuoka University Hospital between January and December 2021. Eligible patients were ≥18 years old, ≥22 weeks of gestation, and treated with MgSO4 for ≥24 h. A total of 66 patients were classified into short-term (<48 h) group (n = 26) and long-term (≥48 h) group (n = 40). The primary outcome was the incidence of acute kidney injury (AKI). Secondary outcomes included changes in serum creatinine level (ΔCr; peak – baseline) and correlations between ΔCr and Mg exposure (duration, daily dose, serum Mg concentration). Neonatal laboratory values at birth were also assessed. AKI occurred in 0% and 2.5% (1/40) of the short- and long-term groups, respectively; the affected case met creatinine-based AKI criteria but impairment was not clinically significant. ΔCr showed a weak positive correlation with treatment duration (ρ = 0.321, P = 0.009), while daily Mg dose and serum Mg levels were not correlated. Long-term group neonates showed higher serum Mg (P = 0.038) and lower Ca (P = 0.045). Long-term MgSO4 tocolysis may cause mild renal burden but appears unlikely to induce clinically significant maternal renal dysfunction under careful monitoring. Maternal and neonatal electrolyte monitoring is advisable during prolonged MgSO4 therapy.

  • Molecular and cellular mechanisms of mitochondria transfer in models of central nervous system disease

    by Takafumi Nakano, Keiichi Irie, Koichi Matsuo, Kenichi Mishima, Yoshihiko Nakamura

    In the central nervous system (CNS), neuronal function and dysfunction are critically dependent on mitochondrial integrity and activity. In damaged or diseased brains, mitochondrial dysfunction reduces adenosine triphosphate (ATP) levels and impairs ATP-dependent neural firing and neurotransmitter dynamics. Restoring mitochondrial capacity to generate ATP may be fundamental in restoring neuronal function. Recent studies in animals and humans have demonstrated that endogenous mitochondria may be released into the extracellular environment and transported or exchanged between cells in the CNS. Under pathological conditions in the CNS, intercellular mitochondria transfer contributes to new classes of signaling and multifunctional cellular activities, thereby triggering deleterious effects or promoting beneficial responses. Therefore, to take full advantage of the beneficial effects of mitochondria, it may be useful to transplant healthy and viable mitochondria into damaged tissues. In this review, we describe recent findings on the mechanisms of mitochondria transfer and provide an overview of experimental methodologies, including tissue sourcing, mitochondrial isolation, storage, and modification, aimed at optimizing mitochondria transplantation therapy for CNS disorders. Additionally, we examine the clinical relevance and potential strategies for the therapeutic application of mitochondria transplantation.


  • Open Access

    Impact of the First Twenty-Four-Hour Area Under the Concentration-Time Curve/Minimum Inhibitory Concentration of Vancomycin on Treatment Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia

    by Mika Higashi, Takafumi Nakano, Keisuke Sato, Yukiomi Eguchi, Norihiro Moriwaki, Mitsuhiro Kamada, Tadahiro Ikeuchi, Susumu Kaneshige, Masanobu Uchiyama, Toshinobu Hayashi, et al.

    Background: Vancomycin regimens are designed to achieve an area under the concentration-time curve/minimum inhibitory concentration (AUC/MIC) ratio ranging between 400 and 600 µg·h/mL in the steady state. However, in cases of critical infections such as bacteremia requiring an early treatment approach, the clinical course may be affected by the AUC/MIC before reaching the steady state, that is, the AUC/MIC values 24 h after the first dose (first 24-h AUC/MIC). This study evaluated the relationship between the first 24-h AUC/MIC and the clinical course of methicillin-resistant Staphylococcus aureus (MRSA) infection. Methods: We retrospectively reviewed the records of patients with MRSA bacteremia in a university hospital between 2015 and 2022. The first 24-h AUC/MIC cutoff was set at 300 µg·h/mL based on the results of early response, and eligible patients were divided into groups with a first 24-h AUC/MIC either < 300 µg·h/mL (< 300 group, n = 32) or ≥ 300 µg·h/mL (≥ 300 group, n = 38). The primary endpoint was the rate of treatment efficacy, and the secondary endpoints were time to clinical and bacteriological improvement and 30-day survival rate. Results: Treatment efficacy and 30-day survival rates were not significantly different between the two groups (78.1% vs. 79.0%, P = 0.933 and 83.9% vs. 87.2%, P = 0.674, respectively). Among patients who showed treatment efficacy, the median time to clinical and bacteriological improvement was 11.5 days and 8.0 days in the < 300 and ≥ 300 groups, respectively; compared to the ≥ 300 group, the < 300 group had a significantly longer time to improvement (P = 0.001). Conclusions: The first 24-h AUC/MIC had no effect on the treatment efficacy and 30-day survival rates. However, the time to clinical and bacteriological improvement was significantly prolonged in the < 300 group, indicating that the first 24-h AUC/MIC does not affect the rate of therapeutic efficacy but may affect the treatment period.


  • Open Access

    Case report of pharmacokinetic analysis of continuous intravenous infusion of fentanyl in a patient with severe burn: burn shock stage complicates pain management

    by Takafumi Nakano, Yasuhisa Oida, Shinichi Morimoto, Kentaro Muranishi, Soichiro Ushio, Takuya Yamashina, Masanobu Uchiyama, Kenichi Mishima, Kiyoyuki Kitaichi, Yoshihiko Nakamura, et al.

    Background: Fentanyl is widely used as an analgesic and sedative for patients with severe burn injuries in intensive care units. However, pharmacokinetic (PK) data for fentanyl, particularly for continuous intravenous infusion during the acute phase of burn injuries, are limited. Here, we report the clinical course and changes in blood fentanyl concentrations during the acute phase in a patient with severe burns treated with continuous intravenous infusion of fentanyl. Case presentation: A woman in her 40s, with burns caused by a gas cylinder explosion, was transported to our hospital. The patient had burn wounds on face, neck, shoulders, and all four extremities, with a total burn area of 39.0%. For pain relief, the patient received a continuous infusion of 0.01 mg/mL fentanyl (20–30 µg/h) with a target blood concentration of 1.0–1.5 ng/mL, but continued to suffer from pain due to burning during the acute phase. We measured the blood fentanyl concentrations and found that all concentrations obtained during the acute phase were subtherapeutic. Notably, during the burn shock stage, blood concentrations of fentanyl were 0.50 ng/mL on day 1 and 0.66 ng/mL on day 2, indicating that the blood concentration did not rise sufficiently for the dosage. From days 0 to 2, the patient was administered a massive fluid load for burn shock. After the burn shock stage resolved, fentanyl concentrations gradually approached the target range, and the pain rating scale improved, even though the fentanyl administration rate remained unchanged (30 µg/h). Conclusions: Major changes in the fluid volumes of body compartments that occur with large burns might increase the volume of fentanyl distribution, thereby lowering its concentration when a standard dose is administered. Our findings indicate that the PK of fentanyl in patients with severe burns can be substantially affected, especially during the shock phase, implying the importance of titrating analgesics for clinical efficacy in the acute phase.

  • Open Access

    Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report

    by Takafumi Nakano, Yoshihiko Nakamura, Keisuke Sato, Yoshito Izutani, Hiroto Iyota, Misaki Aoyagi, Taisuke Kitamura, Toshinobu Hayashi, Koichi Matsuo, Kenichi Mishima, et al.

    Background: In Japan, the use of risperidone in combination with adrenaline is contraindicated, except in cases of anaphylaxis. Therefore, there is limited clinical evidence regarding the interaction of these two drugs. Here, we report the clinical course of a case of adrenaline-resistant anaphylactic shock induced by a contrast medium injection after a risperidone overdose. Case presentation: A man in his 30s was transported to our hospital after attempting suicide by taking 10 mg of risperidone and jumping from a height of 10 m. To determine the location and severity of his injuries, he was injected with an iodinated contrast medium, after which he developed generalized erythema and hypotension and was diagnosed with anaphylactic shock. A 0.5 mg dose of adrenaline was administered with no improvement, followed by another 0.5 mg dose that did not change his blood pressure. After infusion of a sodium bicarbonate solution (8.4%), administration of fresh frozen plasma, and additional administration of adrenaline (0.6–1.2 µg/min), his blood pressure improved, and he recovered from the anaphylactic shock. Conclusions: This was a rare case of a risperidone overdose followed by adrenaline-resistant anaphylactic shock. The resistance is likely associated with the high blood concentration of risperidone. Our findings indicate that the potential for decreased adrenergic responsiveness should be considered in patients undergoing risperidone treatment in the event of anaphylactic shock.